Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease
Annals of Neurology · 2025-12 · 98 (6) · 1237-1248
DOI: 10.1002/ana.78002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 22.09.2025. Verfasst von Omar Abdelmoity und 31 weiteren Autor:innen. Beteiligte Einrichtung: Danforth Undergraduate Campus, Washington University in St. Louis, St. Louis, MO, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Fluorodeoxyglucose F18, Down Syndrome, Brain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCATS NIH HHS, NIDDK NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Objectives
Directly compare the brain glucose patterns seen with [F‐18] fluorodeoxyglucose (FDG) positron emission tomography (PET) between 2 genetically determined forms of Alzheimer's disease: Down syndrome (DS) and autosomal dominant Alzheimer's disease (ADAD).
Methods
Cross‐sectional analyses of FDG were performed in individuals with DS (n = 76) from the Alzheimer Biomarker Consortium‐Down Syndrome (ABC‐DS), ADAD (n = 297), and neurotypical familial controls (n = 188) from the Dominantly Inherited Alzheimer Network (DIAN). Within‐group linear regression models and generalized additive models were performed for select regional FDG uptake measures (isthmus cingulate and inferior parietal, precuneus, middle temporal gyrus, and precentral gyrus). Age, sex, apolipoprotein (APOE) ε4 carrier status, and cortical amyloid burden were included within these analyses.
Results
Even 20 years before expected onset of clinical symptoms, FDG uptake was lower for DS compared to neurotypical familial controls ( p < 0.01). ADAD baseline FDG was similar to neurotypical familial controls until 7 years before expected symptom onset. Both symptomatic individuals with DS and ADAD had lower FDG compared to neurotypical familial controls ( p < 0.01). A higher amyloid burden was associated with lower FDG for both genetic forms, with similar rates of decline in FDG uptake for DS and ADAD who were amyloid positive.
Interpretation
Brain glucose metabolism is substantially lower for people with DS, even in individuals who are cognitively stable. The patterns of FDG decline are distinct in these 2 genetically determined forms of AD. The diagnostic utility of FDG‐PET is specific to the genetic form of AD. ANN NEUROL 2025;98:1237–1248
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Danforth Undergraduate Campus, Washington University in St. Louis, St. Louis, MO, USA.
- Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA.
- Department of Radiology, Washington University in St. Louis, St. Louis, MO, USA.
- Knight Alzheimer Disease Research Center, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
- Hope Center for Neurological Disorders, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.
ORCID-Profile: Omar Abdelmoity, Julie K Wisch, Elizabeth Head, Patrick Lao, Sarah Keefe, Jee Hoon Roh, Gregory S Day, Brian A Gordon
Förderung
- NIA NIH HHS
- NCATS NIH HHS
- NIDDK NIH HHS
Zitieren
APA
Abdelmoity, O., Wisch, J. K., Kennedy, J. T., Goyal, M., Vlassenko, A., Flores, S., Handen, B. L., Head, E., Keator, D., Rafii, M. S., Lao, P., Lai, F., Rosas, H. D., Hartley, S. L., Zaman, S., Brickman, A. M., Tudorascu, D., Lee, J. H., Allegri, R. F., …, & Alzheimer's Biomarker Consortium‐Down Syndrome and the Dominantly Inherited Alzheimer Network (2025). Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease. Annals of Neurology, 98(6), 1237-1248. https://doi.org/10.1002/ana.78002
Vancouver
Abdelmoity O, Wisch JK, Kennedy JT, Goyal M, Vlassenko A, Flores S, et al. Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease. Annals of Neurology. 2025;98(6):1237-1248. doi:10.1002/ana.78002
BibTeX
@article{Abdelmoity2025,
author = {Abdelmoity, Omar and Wisch, Julie K and Kennedy, James T and Goyal, Manu and Vlassenko, Andrei and Flores, Shaney and Handen, Benjamin L and Head, Elizabeth and Keator, David and Rafii, Michael S and Lao, Patrick and Lai, Florence and Rosas, H Diana and Hartley, Sigan L and Zaman, Shahid and Brickman, Adam M and Tudorascu, Dana and Lee, Joseph H and Allegri, Ricardo Francisco and Keefe, Sarah and la Fougere, Christian and Llibre-Guerra, Jorge and Ikeuchi, Takeshi and Morris, John C and Roh, Jee Hoon and Day, Gregory S and Levin, Johannes and Schofield, Peter R and Gordon, Brian A and Benzinger, Tammie L S and Ances, Beau M and Alzheimer's Biomarker Consortium‐Down Syndrome and the Dominantly Inherited Alzheimer Network, Alzheimer's Biomarker Consortium‐Down Syndrome and the Dominantly Inherited Alzheimer Network},
title = {Cross‐Sectional FDG in Down Syndrome and Autosomal Dominant Alzheimer's Disease},
journal = {Annals of Neurology},
year = {2025},
volume = {98},
number = {6},
pages = {1237--1248},
doi = {10.1002/ana.78002}
}
EUVIMED